Brief: Akoya Biosciences And Singapore Translational Cancer Consortium (STCC) Partner On Super Study Designed To Advance Cancer Immunophenotyping For Patients In Singapore
23/04/2025 13:09
April 23 (Reuters) - Akoya Biosciences Inc AKYA.O: AKOYA BIOSCIENCES AND SINGAPORE TRANSLATIONAL CANCER CONSORTIUM (STCC) PARTNER ON SUPER STUDY DESIGNED TO ADVANCE CANCER IMMUNOPHENOTYPING FOR PATIENTS IN SINGAPORE Source text: ID:nGNX6dhdcJ Further company coverage: AKYA.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Akoya Biosciences
See all newsBrief: Akoya Biosciences Inc - On May 20, Receives Unsolicited Acquisition Proposal At $1.40 Per Share From A Third Party- SEC Filing
Akoya Biosciences Inc reports results for the quarter ended March 31 - Earnings Summary
Brief: Akoya Biosciences Q1 Gross Margin 59.3%
Akoya Biosciences Inc expected to post a loss of 20 cents a share - Earnings Preview
Leerink Partners downgrades Quanterix to 'market perform' on Akoya deal risks